MannKind receives FDA approval for updated Afrezza dosing guidance
Tweet Send to a Friend
MannKind Corporation (NASDAQ: MNKD) announced the U.S. Food and Drug Administration approved an update to the prescribing information for Afrezza ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


